The combination ophthalmic solution of fenofibrate and pioglitazone suppressed inflammation, neovascularization, and fibrotic changes by a dual therapeutic effect of the PPARα and PPARγ agonists in the alkali-burned cornea, suggesting a new candidate therapeutic strategy for corneal disease. This evidence concerns the gene PPARA and corneal disorder.